212 related articles for article (PubMed ID: 33839202)
1. Intensity-modulated proton therapy for oropharyngeal cancer reduces rates of late xerostomia.
Cao J; Zhang X; Jiang B; Chen J; Wang X; Wang L; Sahoo N; Zhu XR; Ye R; Blanchard P; Garden AS; Fuller CD; Gunn GB; Frank SJ
Radiother Oncol; 2021 Jul; 160():32-39. PubMed ID: 33839202
[TBL] [Abstract][Full Text] [Related]
2. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Youssef I; Yoon J; Mohamed N; Zakeri K; Press RH; Chen L; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Yu Y; Cohen MA; Dunn LA; Ho AL; Wong RJ; Michel LS; Boyle JO; Singh B; Kriplani A; Ganly I; Sherman EJ; Pfister DG; Fetten J; Lee NY
JAMA Netw Open; 2022 Nov; 5(11):e2241538. PubMed ID: 36367724
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis.
Holliday EB; Kocak-Uzel E; Feng L; Thaker NG; Blanchard P; Rosenthal DI; Gunn GB; Garden AS; Frank SJ
Med Dosim; 2016; 41(3):189-94. PubMed ID: 27158021
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.
Zhang W; Zhang X; Yang P; Blanchard P; Garden AS; Gunn B; Fuller CD; Chambers M; Hutcheson KA; Ye R; Lai SY; Radwan MAS; Zhu XR; Frank SJ
Radiother Oncol; 2017 Jun; 123(3):401-405. PubMed ID: 28549794
[TBL] [Abstract][Full Text] [Related]
5. Potential benefits of scanned intensity-modulated proton therapy versus advanced photon therapy with regard to sparing of the salivary glands in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; de Jong ME; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1216-24. PubMed ID: 20732761
[TBL] [Abstract][Full Text] [Related]
6. Submandibular gland transfer for the prevention of radiation-induced xerostomia in oropharyngeal cancer: Dosimetric impact in the intensity modulated radiotherapy era.
Kutuk T; McAllister NC; Rzepczynski AE; Williams A; Young G; Crawley MB; Rabinowits G; Kaiser A; Contreras JA; Kalman NS
Head Neck; 2022 May; 44(5):1213-1222. PubMed ID: 35243719
[TBL] [Abstract][Full Text] [Related]
7. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
[TBL] [Abstract][Full Text] [Related]
8. Using a reduced spot size for intensity-modulated proton therapy potentially improves salivary gland-sparing in oropharyngeal cancer.
van de Water TA; Lomax AJ; Bijl HP; Schilstra C; Hug EB; Langendijk JA
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e313-9. PubMed ID: 21708427
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome after pencil beam scanning proton therapy and dysphagia/xerostomia NTCP calculations of proton and photon radiotherapy delivered to patients with cancer of the major salivary glands.
Walser MA; Bachmann N; Kluckert J; Köthe A; Tully C; Leiser D; Lomax AJ; Bizzocchi N; Langendijk JA; Weber DC
Br J Radiol; 2023 Aug; 96(1148):20220672. PubMed ID: 37129312
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.
Blanchard P; Garden AS; Gunn GB; Rosenthal DI; Morrison WH; Hernandez M; Crutison J; Lee JJ; Ye R; Fuller CD; Mohamed AS; Hutcheson KA; Holliday EB; Thaker NG; Sturgis EM; Kies MS; Zhu XR; Mohan R; Frank SJ
Radiother Oncol; 2016 Jul; 120(1):48-55. PubMed ID: 27342249
[TBL] [Abstract][Full Text] [Related]
11. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy.
Brodin NP; Kabarriti R; Pankuch M; Schechter CB; Gondi V; Kalnicki S; Guha C; Garg MK; Tomé WA
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(3):540-552. PubMed ID: 30496877
[TBL] [Abstract][Full Text] [Related]
12. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer.
Kawamoto T; Nihei K; Nakajima Y; Kito S; Sasai K; Karasawa K
Auris Nasus Larynx; 2018 Oct; 45(5):1073-1079. PubMed ID: 29397249
[TBL] [Abstract][Full Text] [Related]
13. Correlation between plan quality improvements and reduced acute dysphagia and xerostomia in the definitive treatment of oropharyngeal squamous cell carcinoma.
Cui T; Ward MC; Joshi NP; Woody NM; Murray EJ; Potter J; Dorfmeyer AA; Greskovich JF; Koyfman SA; Xia P
Head Neck; 2019 Apr; 41(4):1096-1103. PubMed ID: 30702180
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and xerostomia after postoperative radiotherapy for oral and oropharyngeal carcinoma.
Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Tu WY; Kirwan J; Mendenhall WM
Head Neck; 2014 Oct; 36(10):1467-73. PubMed ID: 23996878
[TBL] [Abstract][Full Text] [Related]
15. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
[TBL] [Abstract][Full Text] [Related]
16. Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
Michiels S; Barragán AM; Souris K; Poels K; Crijns W; Lee JA; Sterpin E; Nuyts S; Haustermans K; Depuydt T
Radiother Oncol; 2018 Jul; 128(1):161-166. PubMed ID: 28951008
[TBL] [Abstract][Full Text] [Related]
17. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy.
Bagley AF; Ye R; Garden AS; Gunn GB; Rosenthal DI; Fuller CD; Morrison WH; Phan J; Sturgis EM; Ferrarotto R; Wu R; Liu AY; Frank SJ
Radiother Oncol; 2020 Jan; 142():133-139. PubMed ID: 31431373
[TBL] [Abstract][Full Text] [Related]
18. Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes.
Gensheimer MF; Liao JJ; Garden AS; Laramore GE; Parvathaneni U
Radiat Oncol; 2014 Nov; 9():255. PubMed ID: 25424729
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated proton therapy (IMPT) versus intensity-modulated radiation therapy (IMRT) for the treatment of head and neck cancer: A dosimetric comparison.
Nguyen ML; Cantrell JN; Ahmad S; Henson C
Med Dosim; 2021 Autumn; 46(3):259-263. PubMed ID: 33648823
[TBL] [Abstract][Full Text] [Related]
20. Tubarial salivary gland sparing with proton therapy.
Wright CM; Lee DY; Kim M; Barsky AR; Teo BK; Lukens JN; Swisher-McClure S; Lin A
Med Dosim; 2022 Autumn; 47(3):222-226. PubMed ID: 35428548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
